Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split
May 10, 2023 11:15 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals to Present Data on Synergistic Effects of Rencofilstat with Anti-PD1 at AACR 2023
April 17, 2023 16:15 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals Expands SAB with Appointments of Four Liver Disease KOLs
March 30, 2023 08:45 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI Drug Development
March 16, 2023 16:10 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals to Deliver Updates on Ongoing Phase 2 NASH Clinical Program with Rencofilstat at 6th Global NASH Congress
March 02, 2023 16:15 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
EPO Decision to Grant European Patent for Rencofilstat Further Strengthens Hepion’s Patent Portfolio
March 02, 2023 09:15 ET
|
Hepion Pharmaceuticals, Inc.
– Patent Covers 38 European Countries – – Rencofilstat’s Exclusivity May Extend into 2048 – EDISON, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a...
Hepion Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell on February 10, 2023
February 09, 2023 16:15 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Anti-Cancer Potential of Rencofilstat Expanded with Results from Preclinical Multiple Myeloma Studies
January 18, 2023 09:15 ET
|
Hepion Pharmaceuticals, Inc.
- Synergistic activity demonstrated with rencofilstat in combination with first line multiple myeloma drug, bortezomib - EDISON, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals,...
Presentation of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors
January 10, 2023 16:15 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals Receives $3.2 Million in Aggregate Non-Dilutive Funding
January 09, 2023 08:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...